In the present study Apolipoprotein E (ApoE) gene and promoter -491A/T, -427T/C polymorphisms were investigated in order to understand the relationship with AD.

为此本课题对载脂蛋白E基因及其启动子区—491A／T、—427T／C多态性进行了分析，旨在探讨其与国人AD的发病关系。

youdao

Measurements: Total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride, apolipoprotein, and C-reactive protein levels were measured directly.

测量值：总胆固醇、高密度脂蛋白、甘油三酯、载脂蛋白和C反应蛋白直接被检测。

youdao

In December 2012, the FDA approved Juxtapid (lomitapide) to reduce LDL-C, total cholesterol, apolipoprotein B, and non HDL-C in patients with HoFH.

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

The addition of Kynamro helps to reduce low-density lipoprotein-cholesterol (LDL-C), apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol (non HDL-C).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia

KYNAMRO, given as a 200 mg weekly subcutaneous injection, has been approved as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (Apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

FORBES: FDA Approves Mipomersen For Homozygous Familial Hypercholesterolemia